Stock ALBIO BIOSYNEX
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biosynex

Equities

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris
Other stock markets
 11:35:19 2024-05-03 am EDT 		5-day change 1st Jan Change
4.2 EUR -0.47% Intraday chart for Biosynex +2.69% -49.70%
Apr. 30 Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 29 Biosynex: agreement for ProciseDx in North America CF

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 22.84 23.75 151.6 289.9 141 85.85
Enterprise Value (EV) 1 26.04 31.26 130.6 193.2 105.9 125.7
P/E ratio 42.1 x 21.3 x 5.44 x 2.63 x 9.08 x -2.42 x
Yield - - 1.2% 7.6% - -
Capitalization / Revenue 0.73 x 0.69 x 0.99 x 0.76 x 0.72 x 0.79 x
EV / Revenue 0.83 x 0.9 x 0.85 x 0.5 x 0.54 x 1.15 x
EV / EBITDA 31 x 17.4 x 2.84 x 1.36 x 2.28 x -5.25 x
EV / FCF - - 7,609,916 x 2,624,223 x -3,587,726 x -2,402,266 x
FCF Yield - - 0% 0% -0% -0%
Price to Book 0.78 x 0.78 x 2.29 x 1.62 x 0.87 x 0.77 x
Nbr of stocks (in thousands) 9,135 9,135 9,135 11,014 10,220 10,281
Reference price 2 2.500 2.600 16.60 26.32 13.80 8.350
Announcement Date 5/6/19 4/30/20 4/21/21 4/25/22 4/28/23 4/30/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 31.3 34.64 153.9 382.5 196.6 109.3
EBITDA 1 0.8389 1.797 46.02 141.8 46.49 -23.95
EBIT 1 0.3718 1.245 45.73 140.7 38.88 -37.4
Operating Margin 1.19% 3.59% 29.72% 36.77% 19.78% -34.23%
Earnings before Tax (EBT) 1 0.3714 0.8999 43.52 136.9 24.18 -39.68
Net income 1 0.5429 1.116 31.37 104 15.66 -36.95
Net margin 1.73% 3.22% 20.38% 27.19% 7.96% -33.81%
EPS 2 0.0594 0.1221 3.050 10.01 1.520 -3.450
Free Cash Flow - - 17.16 73.61 -29.53 -52.31
FCF margin - - 11.15% 19.24% -15.02% -47.87%
FCF Conversion (EBITDA) - - 37.28% 51.91% - -
FCF Conversion (Net income) - - 54.7% 70.78% - -
Dividend per Share - - 0.2000 2.000 - -
Announcement Date 5/6/19 4/30/20 4/21/21 4/25/22 4/28/23 4/30/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 3.2 7.51 - - - 39.8
Net Cash position 1 - - 21.1 96.7 35.1 -
Leverage (Debt/EBITDA) 3.819 x 4.179 x - - - -1.662 x
Free Cash Flow - - 17.2 73.6 -29.5 -52.3
ROE (net income / shareholders' equity) 1.87% 3.74% 64.8% 88.9% 9.33% -25.5%
ROA (Net income/ Total Assets) 0.58% 1.79% 33% 44.5% 9.18% -9.31%
Assets 1 93.44 62.23 94.97 233.7 170.5 396.7
Book Value Per Share 2 3.200 3.330 7.240 16.30 15.90 10.90
Cash Flow per Share 2 0.2000 0.2000 4.020 12.80 8.500 1.770
Capex - - 9.12 19 30.1 39.5
Capex / Sales - - 5.92% 4.97% 15.3% 36.19%
Announcement Date 5/6/19 4/30/20 4/21/21 4/25/22 4/28/23 4/30/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOSYNEX Stock Biosynex
-49.70% 48.69M
BIOMÉRIEUX Stock bioMérieux
-1.89% 12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.68B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-1.31% 5.29B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+21.82% 5.18B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.89% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.6B
VITROLIFE AB Stock Vitrolife AB
-10.02% 2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. ALBIO Stock
  4. Financials Biosynex